Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A class of deep intronic <i>IGHMBP2</i> variants activate a shared cryptic splice donor, enabling correction of select variants with a single antisense oligonucleotide.

medRxiv : the preprint server for health sciences·2026
Same author

<i>In vivo</i> HSC gene therapy enables sustained eCD4-Ig expression for SIV prevention.

Molecular therapy. Advances·2026
Same author

Cytosine base editing of LPA in transgenic mice averts large deletions.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

Blood advances·2025
Same author

Dominant negative ATP5F1A variants disrupt oxidative phosphorylation causing neurological disorders.

EMBO molecular medicine·2025
Same author

Dominant negative ATP5F1A variants disrupt oxidative phosphorylation causing neurological disorders.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: May 3, 2026

Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5
13:17

Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5

Published on: January 28, 2016

14.8K

Helper-Dependent Adenoviral Vectors.

Amanda Rosewell1, Francesco Vetrini1, Philip Ng1

  • 1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030 USA.

Journal of Genetic Syndromes & Gene Therapy
|February 18, 2014
PubMed
Summary
This summary is machine-generated.

Helper-dependent adenoviral vectors offer efficient gene transfer for long-term expression without toxicity. This review covers their production, applications, and clinical translation challenges for gene therapy.

More Related Videos

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

8.0K
An Efficient Method for Adenovirus Production
10:06

An Efficient Method for Adenovirus Production

Published on: June 10, 2021

16.0K

Related Experiment Videos

Last Updated: May 3, 2026

Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5
13:17

Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5

Published on: January 28, 2016

14.8K
Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
08:14

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

8.0K
An Efficient Method for Adenovirus Production
10:06

An Efficient Method for Adenovirus Production

Published on: June 10, 2021

16.0K

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Gene Therapy

Background:

  • Helper-dependent adenoviral vectors (HDAdVs) are engineered viral gene delivery systems.
  • HDAdVs lack viral coding sequences, enabling large transgene capacity and safe, long-term expression.
  • Their ability to transduce diverse cell types efficiently makes them promising for therapeutic applications.

Purpose of the Study:

  • To review the current state of helper-dependent adenoviral vector technology.
  • To discuss production methods, diverse applications, and challenges in clinical translation.
  • To identify future research directions and address unanswered questions in gene transfer.

Main Methods:

  • Review of existing literature on helper-dependent adenoviral vector production and application.
  • Analysis of data regarding transduction efficiency, transgene expression, and toxicity.
  • Evaluation of obstacles to clinical translation and proposed solutions.

Main Results:

  • HDAdVs demonstrate efficient transduction across various cell types and species, independent of cell cycle.
  • Long-term transgene expression is achievable with minimal chronic toxicity.
  • Significant progress has been made in vector production and overcoming clinical hurdles.

Conclusions:

  • Helper-dependent adenoviral vectors are a powerful, non-integrating platform for gene transfer and therapy.
  • Further research and development are needed to fully realize their clinical potential.
  • Addressing production scalability and immunogenicity remains key for successful translation.